Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 31.55
(-0.94%)
TWD 31.55
(-0.94%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.09 Billion TWD | -0.01% |
| 2022 | 1.09 Billion TWD | 22.8% |
| 2021 | 888.7 Million TWD | 1.5% |
| 2020 | 875.53 Million TWD | -6.94% |
| 2019 | 940.84 Million TWD | 13.99% |
| 2018 | 825.38 Million TWD | 1.87% |
| 2017 | 810.25 Million TWD | 2.58% |
| 2016 | 789.91 Million TWD | 0.5% |
| 2015 | 785.98 Million TWD | -27.47% |
| 2014 | 1.08 Billion TWD | 12.38% |
| 2013 | 964.28 Million TWD | 24.91% |
| 2012 | 772.01 Million TWD | 11.27% |
| 2011 | 693.8 Million TWD | -0.05% |
| 2010 | 694.16 Million TWD | -4.11% |
| 2009 | 723.89 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 279.32 Million TWD | -12.31% |
| 2024 Q1 | 318.52 Million TWD | 12.48% |
| 2023 FY | 1.09 Billion TWD | -0.01% |
| 2023 Q1 | 287.19 Million TWD | 4.81% |
| 2023 Q2 | 246.26 Million TWD | -14.25% |
| 2023 Q3 | 274.58 Million TWD | 11.5% |
| 2023 Q4 | 283.19 Million TWD | 3.13% |
| 2022 Q3 | 270.16 Million TWD | -5.91% |
| 2022 Q1 | 259.97 Million TWD | 8.52% |
| 2022 FY | 1.09 Billion TWD | 22.8% |
| 2022 Q4 | 274.01 Million TWD | 1.43% |
| 2022 Q2 | 287.14 Million TWD | 10.45% |
| 2021 Q4 | 239.56 Million TWD | 12.33% |
| 2021 Q3 | 213.26 Million TWD | -6.98% |
| 2021 FY | 888.7 Million TWD | 1.5% |
| 2021 Q1 | 206.59 Million TWD | 19.93% |
| 2021 Q2 | 229.28 Million TWD | 10.98% |
| 2020 Q4 | 172.26 Million TWD | -24.78% |
| 2020 Q1 | 247.24 Million TWD | -14.19% |
| 2020 Q2 | 227 Million TWD | -8.18% |
| 2020 FY | 875.53 Million TWD | -6.94% |
| 2020 Q3 | 229.02 Million TWD | 0.89% |
| 2019 Q4 | 288.11 Million TWD | 31.93% |
| 2019 Q3 | 218.39 Million TWD | 0.91% |
| 2019 FY | 940.84 Million TWD | 13.99% |
| 2019 Q1 | 217.92 Million TWD | -7.38% |
| 2019 Q2 | 216.42 Million TWD | -0.69% |
| 2018 FY | 825.38 Million TWD | 1.87% |
| 2018 Q2 | 190.64 Million TWD | -8.42% |
| 2018 Q1 | 208.16 Million TWD | -6.66% |
| 2018 Q4 | 235.29 Million TWD | 23.01% |
| 2018 Q3 | 191.28 Million TWD | 0.34% |
| 2017 Q1 | 183.43 Million TWD | -18.37% |
| 2017 Q4 | 223.01 Million TWD | 7.29% |
| 2017 Q3 | 207.86 Million TWD | 6.09% |
| 2017 FY | 810.25 Million TWD | 2.58% |
| 2017 Q2 | 195.94 Million TWD | 6.82% |
| 2016 Q3 | 191.1 Million TWD | 0.33% |
| 2016 FY | 789.91 Million TWD | 0.5% |
| 2016 Q4 | 224.7 Million TWD | 17.58% |
| 2016 Q2 | 190.47 Million TWD | 3.72% |
| 2016 Q1 | 183.63 Million TWD | -30.31% |
| 2015 FY | 785.98 Million TWD | -27.47% |
| 2015 Q1 | 153.58 Million TWD | -50.56% |
| 2015 Q2 | 198.31 Million TWD | 29.12% |
| 2015 Q4 | 263.49 Million TWD | 54.47% |
| 2015 Q3 | 170.58 Million TWD | -13.98% |
| 2014 Q4 | 310.66 Million TWD | 79.4% |
| 2014 Q2 | 330.93 Million TWD | 23.09% |
| 2014 Q1 | 268.85 Million TWD | 0.04% |
| 2014 FY | 1.08 Billion TWD | 12.38% |
| 2014 Q3 | 173.16 Million TWD | -47.67% |
| 2013 Q1 | 169.54 Million TWD | -10.97% |
| 2013 Q3 | 297.53 Million TWD | 30.23% |
| 2013 Q4 | 268.74 Million TWD | -9.68% |
| 2013 FY | 964.28 Million TWD | 24.91% |
| 2013 Q2 | 228.47 Million TWD | 34.76% |
| 2012 Q4 | 190.43 Million TWD | -8.78% |
| 2012 Q3 | 208.75 Million TWD | 3.5% |
| 2012 FY | 772.01 Million TWD | 11.27% |
| 2012 Q2 | 201.69 Million TWD | 17.24% |
| 2012 Q1 | 172.03 Million TWD | 0.04% |
| 2011 Q2 | 172.59 Million TWD | -4.22% |
| 2011 Q1 | 180.19 Million TWD | -1.99% |
| 2011 Q3 | 169.05 Million TWD | -2.05% |
| 2011 Q4 | 171.96 Million TWD | 1.73% |
| 2011 FY | 693.8 Million TWD | -0.05% |
| 2010 Q3 | 158.01 Million TWD | -14.93% |
| 2010 FY | 694.16 Million TWD | -4.11% |
| 2010 Q1 | 166.55 Million TWD | 0.0% |
| 2010 Q4 | 183.84 Million TWD | 16.35% |
| 2010 Q2 | 185.74 Million TWD | 11.52% |
| 2009 FY | 723.89 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Apex Biotechnology Corp. | 531.11 Million TWD | -105.462% |
| Panion & Bf Biotech Inc. | 912.56 Million TWD | -19.58% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 757.3 Million TWD | -44.095% |
| GenMont Biotech Incorporation | 177.33 Million TWD | -515.353% |
| Abnova (Taiwan) Corporation | 173.91 Million TWD | -527.458% |
| Adimmune Corporation | 410.93 Million TWD | -165.551% |
| Tanvex BioPharma, Inc. | 59.7 Million TWD | -1727.847% |
| Polaris Group | -137.9 Million TWD | 891.323% |
| Energenesis Biomedical CO.,LTD. | 5.22 Million TWD | -20777.042% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -5997.352% |
| PELL Bio-Med Technology Co. Ltd. | -26.14 Million TWD | 4274.61% |